Loading…
Tianjin pharma group known for Xuebijing, a TCM injection used in hospital intensive-care and sepsis treatment.
Tianjin pharma group known for Xuebijing, a TCM injection used in hospital intensive-care and sepsis treatment.
Sells Xuebijing, a Chinese-medicine injection given in hospital intensive care, to hospitals through distributors, so sales depend on staying on China's reimbursement lists and on how widely doctors use it. A retail pharmacy chain adds a second line selling other makers' medicines to consumers.
In one line: A Chinese hospital-injectable TCM maker.
Moat: narrow (brand, regulatory licence). Established hospital-injectable brand with wide ICU adoption and reimbursement listing.
Headquarters: Tianjin, China · Employees: 4,852
Size Tianjin Chase Sun Pharmaceutical (300026.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.32B, the 1823rd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥3.22 on 6 Nov 2026.
Performance Over six months the shares fell 5.8%, against -14.8% for the median peer and -16.4% for the China market (cap-weighted) — 7th highest of 21 in its peer set.
Growth Revenue fell 29.0% over the last twelve months (peer median +15.6%); the operating margin is 2.8% (peer median 1.9%).
Valuation It trades at 23.0× forward earnings against a peer median of 12.5× (2nd most expensive of 8).
Price implies For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is -5%, so the hurdle is +14 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 4.0 points below its cost of capital (7.6% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥3.90B | CN¥4.90B | CN¥5.74B | CN¥6.07B | CN¥6.61B |
| Revenue growth | — | -15% | -5% | -8% | — |
| Gross profit | CN¥2.61B | CN¥2.65B | CN¥2.81B | CN¥3.07B | CN¥3.60B |
| EBITDA | n/a | CN¥523M | CN¥447M | CN¥862M | CN¥1.06B |
| Net income | CN¥25.8M | CN¥18.5M | CN¥21.5M | CN¥507M | CN¥624M |
| Free cash flow | CN¥659M | CN¥681M | CN¥654M | CN¥1.18B | -CN¥23.2M |
| Capital expenditure | CN¥110M | CN¥130M | CN¥193M | CN¥347M | CN¥770M |
| Total debt | CN¥374M | CN¥540M | CN¥897M | CN¥1.58B | CN¥2.13B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Tianjin Chase Sun Pharmaceutical 300026.SZ | $1.32B | -6% | -29% | 3% | 23.0× | 8.5% |
| Shijiazhuang Yiling Pharmaceutical 002603.SZ | $4.02B | -6% | +32% | 21% | 18.1× | -3.2% |
| Tasly Pharmaceutical 600535.SS | $3.20B | -5% | -4% | 19% | 16.5× | -7.6% |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | $6.48B | 0% | +4% | 14% | 12.8× | -6.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300026.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.3% | -7.5% | 7th highest of 21 |
| 6-month return | -5.8% | -14.8% | 7th highest of 21 |
| Distance from 52-week high | -19.3% | -41.6% | 4th highest of 21 |
| Revenue growth (TTM) | -29.0% | +15.6% | 2nd lowest of 17 |
| Operating margin | 2.8% | 1.9% | 9th highest of 17 |
| Forward P/E | 23.0× | 12.5× | 2nd most expensive of 8 |
| Growth the price implies (Req g, 7 yrs) | 8.5% | 0.3% | 3rd most demanding of 8 |
| Growth delivered (Del g) | -5.3% | +13.8% | lowest of 8 |
| Hurdle (Req g minus delivered) | +13.8 pp | -16.3 pp | most demanding of 8 |
| ROIC minus cost of capital | -4.0 pp | -5.2 pp | 9th highest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Tianjin Chase Sun Pharmaceutical 300026.SZ | China | $1.32B | -6% | -29% | 3% | 23.0× | 8.5% | -5.3% |
| C.Q. Pharmaceutical 000950.SZ | China | $1.32B | -12% | -3% | 1% | 19.7× | n/a | n/a |
| Hanall Biopharma 009420.KS | South Korea | $1.34B | -25% | +5% | 3% | n/a | n/a | n/a |
| Lotus Pharmaceutical 1795.TW | Taiwan | $1.34B | -26% | +49% | 24% | 8.4× | -2.4% | +13.8% |
| Idorsia IDIA.SW | Switzerland | $1.34B | -5% | -5% | -70% | n/a | n/a | n/a |
| Zhejiang Xianju Pharmaceutical 002332.SZ | China | $1.34B | +2% | +8% | 11% | 18.6× | 0.3% | -1.3% |
| Chongqing Genrix Biopharmaceutical 688443.SS | China | $1.34B | -10% | +256% | -27% | n/a | n/a | n/a |
| Phibro Animal Health PAHC | United States | $1.34B | -18% | +17% | 13% | 9.1× | -7.4% | +12.7% |
| Sinopep-Allsino Bio Pharmaceutical 688076.SS | China | $1.31B | -7% | +14% | 19% | 12.5× | 4.0% | +27.9% |
| Voronoi 310210.KS | South Korea | $1.31B | -66% | +24% | -1,947% | n/a | n/a | n/a |
| Shanghai OPM Biosciences 688293.SS | China | $1.35B | +26% | +133% | 11% | 50.3× | 26.1% | +23.1% |
| LB Pharmaceuticals LBRX | United States | $1.36B | +31% | n/a | n/a | n/a | n/a | n/a |
| Avalyn Pharma AVLN | United States | $1.29B | +7% | n/a | n/a | n/a | n/a | n/a |
| PYC Therapeutics PYC.AX | Australia | $1.28B | +31% | n/a | n/a | n/a | n/a | n/a |
| D&D Pharmatech 347850.KS | South Korea | $1.28B | -49% | -71% | -1,368% | n/a | n/a | n/a |
| GH Research GHRS | United States | $1.28B | -13% | n/a | n/a | n/a | n/a | n/a |
| Mabwell (Shanghai) Bioscience 2493.HK | Hong Kong | $1.37B | -32% | +21% | -127% | n/a | n/a | n/a |
| Nektar Therapeutics NKTR | United States | $1.27B | -54% | -27% | -239% | n/a | n/a | n/a |
| Innoviva INVA | United States | $1.38B | -17% | +18% | 36% | 9.4× | -15.4% | +3.9% |
| Celltrion Pharm 068760.KS | South Korea | $1.27B | -29% | +14% | 11% | n/a | 11.7% | +18.1% |
| Ascentage Pharma Group International 6855.HK | Hong Kong | $1.39B | -33% | +70% | -220% | n/a | n/a | n/a |